Key TakeawaysEli Lilly will acquire Verve for roughly $1 billionVerve is developing a one-time gene-editing treatment for ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Eli Lilly's $1.3B acquisition of Verve Therapeutics caused a sharp rally, but with shares above the buyout price, I recommend ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

Streaming Finally Outpaces Traditional TV. The Leading Platform Might Surprise You. YouTube represented 12.5% of all television viewing in May-the highest share of TV for any streamer to date. The new ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal ...

The plane maker is betting that demand for aircraft will continue to fuel growth in coming years. The systems will be jointly developed and produced by the two companies, with suppliers and industrial ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

Sitting at her perch from the “Massachusetts Pavilion,” Gov. Maura Healey briefly gestured Tuesday to nearby competitors with flashy booths set up at the BIO International Convention, ...